MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine.
In: Neurological Sciences, Jg. 42 (2021-09-01), Heft 9, S. 3533-3535
Online
academicJournal
Zugriff:
Background: The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs' immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the post-infection development of immunity against the virus under these treatments due to their interaction with the immune system. Methods: We report two asymptomatic cases of COVID-19 in patients with relapsing–remitting multiple sclerosis (RRMS) shortly after starting cladribine therapy, both developed anti-SARS-CoV-2 antibody response. Results: Patients with MS who are under newly initiated treatment with cladribine tablets may experience an asymptomatic COVID-19 infection and they may develop immunity against SARS-CoV-2. Conclusion: These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]
Titel: |
MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine.
|
---|---|
Autor/in / Beteiligte Person: | Seferoğlu, Meral ; Ethemoğlu, Özlem ; Turan, Ömer Faruk ; Siva, Aksel |
Link: | |
Zeitschrift: | Neurological Sciences, Jg. 42 (2021-09-01), Heft 9, S. 3533-3535 |
Veröffentlichung: | 2021 |
Medientyp: | academicJournal |
ISSN: | 1590-1874 (print) |
DOI: | 10.1007/s10072-021-05409-6 |
Sonstiges: |
|